DV
Dividend Vision

MDGL — Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (MDGL)

Total return is 59.5% over the past 19.5 years, 606.7 points behind SPY at 666.2%. Its deepest 1-year drawdown was 29.4%.

This is a single-stock equity fund focused on Madrigal Pharmaceuticals, a healthcare company, rather than a diversified ETF holding a basket of securities. The fund does not currently pay distributions and lacks published yield or expense ratio data. This structure appeals primarily to investors seeking concentrated exposure to a single pharmaceutical company rather than those pursuing dividend income.

MDGL key facts

Asset type
Stock
Asset class
Equity
Inception date
02/06/2007
Last close
$507.56
Market cap
$11,726,730,240
Average volume
234700.0
Payment date
07/25/2016
Beta
-1.003
Payout ratio
0.0
Forward P/E
666.6667
EPS
$-14.00